IPSC Strangle Strategy
IPSC (Century Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC (Century Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $197.4M, a beta of 1.56 versus the broader market, a 52-week range of 0.435-3.04, average daily share volume of 1.2M, a public-listing history dating back to 2021, approximately 140 full-time employees. These structural characteristics shape how IPSC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.56 indicates IPSC has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on IPSC?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current IPSC snapshot
As of May 15, 2026, spot at $2.33, ATM IV 50.00%, IV rank 6.11%, expected move 14.33%. The strangle on IPSC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on IPSC specifically: IPSC IV at 50.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a IPSC strangle, with a market-implied 1-standard-deviation move of approximately 14.33% (roughly $0.33 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IPSC expiries trade a higher absolute premium for lower per-day decay. Position sizing on IPSC should anchor to the underlying notional of $2.33 per share and to the trader's directional view on IPSC stock.
IPSC strangle setup
The IPSC strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IPSC near $2.33, the first option leg uses a $2.45 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IPSC chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IPSC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.45 | N/A |
| Buy 1 | Put | $2.21 | N/A |
IPSC strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IPSC strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IPSC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on IPSC
Strangles on IPSC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IPSC chain.
IPSC thesis for this strangle
The market-implied 1-standard-deviation range for IPSC extends from approximately $2.00 on the downside to $2.66 on the upside. A IPSC long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IPSC IV rank near 6.11% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IPSC at 50.00%. As a Healthcare name, IPSC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IPSC-specific events.
IPSC strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IPSC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IPSC alongside the broader basket even when IPSC-specific fundamentals are unchanged. Always rebuild the position from current IPSC chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IPSC?
- A strangle on IPSC is the strangle strategy applied to IPSC (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IPSC stock trading near $2.33, the strikes shown on this page are snapped to the nearest listed IPSC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IPSC strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IPSC strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 50.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IPSC strangle?
- The breakeven for the IPSC strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IPSC market-implied 1-standard-deviation expected move is approximately 14.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IPSC?
- Strangles on IPSC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IPSC chain.
- How does current IPSC implied volatility affect this strangle?
- IPSC ATM IV is at 50.00% with IV rank near 6.11%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.